Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarkers, has announced the opening of a new office in Cambridge, Massachusetts, marking a significant expansion of its U.S. operations. This strategic move is designed to enhance IAG’s proximity to biotechnology and pharmaceutical companies, thereby fostering stronger partnerships and providing enhanced local support for clinical trials throughout the region.
The Cambridge office will bolster IAG’s efforts across various therapeutic areas, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. By situating operations in this key location, the company aims to work more closely with sponsors and contract research organizations engaged in Phase I–III clinical trials and imaging-focused development programs. Additionally, IAG plans to generate local employment opportunities, with recruitment projected in clinical imaging operations, data science, regulatory support, and business development over the coming 12 to 24 months.
IAG’s new office will provide comprehensive imaging services, such as clinical trial design consultation, optimization of imaging protocols, centralized image analysis, and delivery of data that complies with regulatory standards. The company’s presence in the vibrant Boston life-sciences ecosystem is anticipated to enhance collaboration with biotechnology firms, pharmaceutical entities, academic institutions, and clinical research centers.
Operating globally, IAG supports clinical trials across North America, Europe, and the Asia-Pacific region, partnering with pharmaceutical, biotechnology, and medtech companies, as well as CROs, on multi-center studies. Its international operations focus on delivering standardized imaging protocols, harmonized data, and consistent imaging analyses across worldwide trials.
Founded in 2007 and headquartered in London, Image Analysis Group functions as an imaging Clinical Research Organization (iCRO). It provides imaging-based clinical trial endpoints for pharmaceutical, biotechnology, and medical technology companies. The company’s DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight across various indications such as oncology, inflammatory diseases, musculoskeletal, cardiometabolic, and rare diseases.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.
